Nippon Life India Asset Management rallied 3.89% to Rs 659.25 after the company’s consolidated net profit jumped 40.99% to Rs 332.33 crore in Q1 FY25 as compared with Rs 235.72 crore posted in Q1 FY24.
Posts in category Business Standard
Vedanta declared preferred bidder for composite license of critical mineral blocks (22-07-2024)
As per the tender document, the Gollarahatti-Mallenahalli Nickel Chromium and PGE Block is at G4 level of exploration with total area of 1238.122 hectares for the block, while Genjana Nickel, Chromium
and PGE Block is at G3 level of exploration with total area of 788.85 hectares for the block.
Yes Bank gains as Q1 PAT climbs 47% YoY to Rs 502 crore (22-07-2024)
Yes Bank advanced 3.39% to Rs 25.62 after its standalone net profit jumped 46.69% to Rs 502.43 crore on 17.59% rise in total income to Rs 8,918.14 crore in Q1 FY25 over Q1 FY24.
Emami Ltd Spikes 4.69% (22-07-2024)
Emami Ltd has added 19.22% over last one month compared to 8.84% gain in BSE Fast Moving Consumer Goods index and 3.8% rise in the SENSEX
Reliance Industries Ltd Slides 2.78%, BSE Energy index Shed 1.43% (22-07-2024)
Reliance Industries Ltd has added 4% over last one month compared to 4.75% gain in BSE Energy index and 3.8% rise in the SENSEX
Nomura picks BPCL as top OMC stock on attractive valuation; sees 21% upside (22-07-2024)
Analysts said BPCL reported a robust performance in the June quarter (Q1FY25) despite a challenging environment.
JSW Neo Energy wins LoA for 500 MW solar power project and 250 MW energy storage system (22-07-2024)
From Solar Energy Corporation of India
JSW Neo Energy receives LoA for 300 MW solar power project (22-07-2024)
From Karnataka Renewable Energy Development
Fineotex Chemical raises Rs 342.5 cr via preferential allotment of shares and warrants (22-07-2024)
Fineotex Chemical announced the successful fund raising of Rs 342.5 crore through a preferential allotment of equity shares and convertible warrants.
Zydus receives Mexican regulatory approval for cancer drug – Bhava (22-07-2024)
Zydus Lifesciencesannounced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for Bhava™, a Bevacizumab biosimilar.